We are live on ! Find out more
ACA

Avoro Capital Advisors Portfolio holdings

AUM $10.2B
1-Year Est. Return 149.19%
This Fund
S&P 500
This Quarter Est. Return
-0.89%
1 Year Est. Return
+149.19%
3 Year Est. Return
+425.03%
5 Year Est. Return
+775.33%
10 Year Est. Return
+45,729.2%
AUM
$5.06B
AUM Growth
-$417M
Cap. Flow
-$118M
Cap. Flow %
-2.33%
Top 10 Hldgs %
72.91%
Holding
44
New
1
Increased
20
Reduced
5
Closed
4

Top Buys

Rank Stock Value
1
FOLD
Amicus Therapeutics
FOLD
+$51.9M
2
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$47.7M
3
RARE icon
Ultragenyx Pharmaceutical
RARE
+$32M
4
SGEN
Seagen Inc. Common Stock
SGEN
+$30.3M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$19.8M

Top Sells

Rank Stock Value
1
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$161M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$142M
3
ACAD icon
Acadia Pharmaceuticals
ACAD
+$55.1M
4
PRAX icon
Praxis Precision Medicines
PRAX
+$22M
5
UTHR icon
United Therapeutics
UTHR
+$12.2M

Sector Composition

Rank Sector Weight
1 Healthcare 98.38%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
UTHR icon
1
United Therapeutics
UTHR
$25.9B
$700M 13.83%
2,970,000
-60,000
-2% -$12.2M
ARGX icon
2
argenx
ARGX
$54.9B
$479M 9.48%
1,265,555
+10,555
+0.8% +$3.4M
APLS
3
DELISTED
Apellis Pharmaceuticals
APLS
$443M 8.76%
9,805,000
+355,000
+4% +$16.2M
HZNP
4
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$399M 7.88%
5,000,000
-1,500,000
-23% -$142M
MRTX
5
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$373M 7.36%
5,550,555
+225,555
+4% +$14.3M
FOLD
6
DELISTED
Amicus Therapeutics
FOLD
$288M 5.69%
26,800,000
+6,300,000
+31% +$51.9M
BMRN icon
7
BioMarin Pharmaceuticals
BMRN
$11.9B
$272M 5.38%
3,284,000
+249,000
+8% +$19.8M
SGEN
8
DELISTED
Seagen Inc. Common Stock
SGEN
$270M 5.33%
1,525,000
+210,000
+16% +$30.3M
SRPT icon
9
Sarepta Therapeutics
SRPT
$1.64B
$254M 5.02%
3,390,000
+255,000
+8% +$18.8M
ASND icon
10
Ascendis Pharma A/S
ASND
$16.6B
$211M 4.18%
2,275,000
+75,000
+3% +$7.07M
ALNY icon
11
Alnylam Pharmaceuticals
ALNY
$38.1B
$198M 3.92%
1,360,000
+60,000
+5% +$8.51M
XENE icon
12
Xenon Pharmaceuticals
XENE
$6.16B
$149M 2.95%
4,900,000
-85,000
-2% -$2.57M
MDGL icon
13
Madrigal Pharmaceuticals
MDGL
$12.4B
$110M 2.17%
1,535,000
+110,000
+8% +$8.09M
IOVA icon
14
Iovance Biotherapeutics
IOVA
$2.03B
$102M 2.01%
9,220,000
+95,000
+1% +$1.24M
KURA icon
15
Kura Oncology
KURA
$785M
$88M 1.74%
4,800,000
– –
KRYS icon
16
Krystal Biotech
KRYS
$10.6B
$70.6M 1.39%
1,075,000
+70,000
+7% +$4.35M
BCRX icon
17
BioCryst Pharmaceuticals
BCRX
$2.43B
$68.8M 1.36%
6,500,000
+4,625,000
+247% +$47.7M
ISEE
18
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$68.5M 1.35%
7,120,000
-130,000
-2% -$1.63M
XBI icon
19
State Street SPDR S&P Biotech ETF
XBI
$9.97B
$66.8M 1.32%
900,000
-2,150,000
-70% -$161M
RARE icon
20
Ultragenyx Pharmaceutical
RARE
$2.49B
$44.7M 0.88%
750,000
+520,000
+226% +$32M
PMVP icon
21
PMV Pharmaceuticals
PMVP
$57.6M
$44.2M 0.87%
3,100,000
+900,000
+41% +$13.1M
SNDX icon
22
Syndax Pharmaceuticals
SNDX
$1.68B
$42.8M 0.84%
2,222,222
+1,722
+0.1% +$28.7K
MRSN
23
DELISTED
Mersana Therapeutics
MRSN
$34.9M 0.69%
302,000
+30,000
+11% +$2.82M
MNKD icon
24
MannKind Corp
MNKD
$1.2B
$34.7M 0.69%
9,100,000
+300,000
+3% +$1.1M
GLUE icon
25
Monte Rosa Therapeutics
GLUE
$1.82B
$32M 0.63%
3,311,536
+102
+0% +$1.02K
1
2

Similar funds

IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
OIA
OneDigital Investment Advisors Overland Park, Kansas $10.2B AUM 16.58% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
LWCFA
Loring Wolcott & Coolidge Fiduciary Advisors Boston, Massachusetts $9.98B AUM 4.97% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Avoro Capital Advisors's Q2 2022 Portfolio in Review

As of Q2 2022, Avoro Capital Advisors held 44 positions worth $5.06B, down 7.6% from $5.48B the previous quarter. Its ten largest holdings account for 73% of the portfolio.

Avoro Capital Advisors's Q2 2022 filing shows 1 new, 20 increased, 5 reduced and 4 closed positions. Its largest new stake was Relay Therapeutics: 400,000 shares worth $6.7M. The largest sale was State Street SPDR S&P Biotech ETF, an estimated $161M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 94% a quarter earlier.

  • Avoro Capital Advisors's largest Q2 2022 buy was Relay Therapeutics: 400,000 shares worth $6.7M.
  • Avoro Capital Advisors added most to Amicus Therapeutics in Q2 2022, an estimated $51.9M increase.
  • Avoro Capital Advisors's biggest Q2 2022 reduction was State Street SPDR S&P Biotech ETF, cutting an estimated $161M.
  • Avoro Capital Advisors fully exited Acadia Pharmaceuticals in Q2 2022, selling an estimated $55.1M.
  • Avoro Capital Advisors's ten largest holdings make up 73% of its $5.06B portfolio in Q2 2022.
  • Avoro Capital Advisors opened 1 new position and closed 4 in Q2 2022.
  • Avoro Capital Advisors's portfolio value fell 7.6% quarter-over-quarter to $5.06B.

Based on Avoro Capital Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.